SAYFUR

This brand name is authorized in Nigeria.

Active ingredients

The drug SAYFUR contains one active pharmaceutical ingredient (API):

1	Cefuroxime UNII Z49QDT0J8Z - CEFUROXIME AXETIL
	Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
	Read more about Cefuroxime

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-6851	Powder for suspension	SAYFUR POWDER FOR ORAL SUSPENSION 125mg/5ML PWD_F_SOL 125 mg/5 mL 1 X 100ML	35 RNW-PP-251144 SAYFUR POWDER FOR ORAL SUSPENSION 125mg/5ML CEFUROXIME AXETIL 125MG/5ML CEFUROXIME AXETIL 125MG/5ML, ASPARTAME, XANTHAN GUM, ACESULFAME POTASSIUM, POVIDONE K30, STEARIC ACID, SUCROSE, PURIFIED WATER B4-6851 Drugs ANTIINFECTIVES FOR SYSTEMIC USE Imported Products 1100ML Prescription Only Medicine (POM) 3/2/2022 SEAL HEALTHCARE LIMITED, 2, ASIMOLOWE STREET, OFF 5TH AVENUE, ABESAN ESTATE, LAGOS 80204011 femoade4real@yahoo.com FINECURE PHARMACEUTICAL LTD, VILLAGE SHIMLA PISTAUR, MALSA ROAD, KICHHA, UDHAMSINGH NAGAR, UTTARAKHAND-263148,INDIA, India	28/03/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DC02	Cefuroxime	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DC Second-generation cephalosporins
Discover more medicines within J01DC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-6851